Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun;28(6):3375-3382.
doi: 10.1245/s10434-020-09565-5. Epub 2021 Feb 24.

The Landmark Series: Multimodal Therapy for Esophageal Cancer

Caitlin T Demarest  1 , Andrew C Chang  2
Affiliations
Review

The Landmark Series: Multimodal Therapy for Esophageal Cancer

Caitlin T Demarest et al. Ann Surg Oncol. 2021 Jun.

Abstract

Introduction: Esophagectomy is the mainstay of treatment for patients with resectable esophageal cancer, and chemotherapy and chemoradiation have become essential adjuncts to improve survival. Controversy remains regarding the optimal perioperative therapy.

Methods: This review focuses on three landmark, randomized, controlled trials that have greatly influenced esophageal cancer management and established chemotherapy and chemoradiotherapy as standard of care: Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial (MAGIC); The United Kingdom Medical Research Council Esophageal Cancer Trial (OEO2); and Chemoradiotherapy for Oesophageal Cancer Followed by Surgery Study (CROSS).

Results: The findings from these landmark studies are reviewed and summarized.

Conclusion: Chemotherapy regimens are heterogeneous but centered around platinum-based therapy and should be included in the management for all appropriate patients. Ongoing and future studies will further delineate the roles of various chemo- and chemoradiotherapy regimens and also will investigate the promising area of immunotherapy in the treatment of esophageal cancer.

Keywords: Adjuvant therapy; Chemotherapy; Esophageal cancer; Esophagectomy; Esophagogastrectomy; Neoadjuvant therapy; Radiation therapy; Review article.

PubMed Disclaimer

References

    1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917. - DOI
    1. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349:2241–52. - DOI
    1. Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med. 1997;337:161–7. - DOI
    1. Oppedijk V, van der Gaast A, van Lanschot JJ, et al. Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials. J Clin Oncol. 2014;32:385–91. - DOI
    1. van der Wilk BJ, Eyck BM, Lagarde SM, et al. The optimal neoadjuvant treatment of locally advanced esophageal cancer. J Thorac Dis. 2019;11:S621–31. - DOI

MeSH terms

LinkOut - more resources